Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2018 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018

PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the...
April 16, 2018 14:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting

- Preclinical testing raises no safety concerns for MAGE A4 -- Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity - PHILADELPHIA, Pa. and OXFORD,...
April 12, 2018 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Changes to Board of Directors

PHILADELPHIA, Pa. and OXFORD, U.K., April 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that, in a planned...
April 06, 2018 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

PHILADELPHIA, Pa. and OXFORD, U.K., April 06, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present two posters summarizing...
March 15, 2018 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells

PHILADELPHIA and OXFORD, U.K., March 15, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported three partial responses (two...
March 15, 2018 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update

- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing...
March 05, 2018 12:12 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018

PHILADELPHIA and OXFORD, United Kingdom, March 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results...
January 08, 2018 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company

PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
January 08, 2018 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose

PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data...
January 04, 2018 08:00 ET | Source: Adaptimmune Therapeutics plc

Paul Stead Joins Adaptimmune as Vice President of Business Development

PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B....